Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
European Medicines Agency (EMA) accepts marketing authorisation application for daprodustat
The EMA has validated the MAA for daprodustat, for the treatment of patients with anaemia of chronic kidney disease.
-
GSK introduces Haleon to investors
Global leader in consumer health set to be a newly independent company
-
GSK provides further update on phase III RSV maternal vaccine candidate programme
Further to the voluntary pause shared on February 18, the Company has decided to stop enrolment and vaccination in trials
-
Medicago and GSK announce the approval by Health Canada of COVIFENZ®, an adjuvanted plant-based COVID-19 vaccine
A vaccine manufactured in plants and developed in Canada
-
Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine
Sanofi and GSK today announce that they intend to submit data from both their booster and Phase 3 efficacy trials
-
GSK announces independent Consumer Healthcare company is to be called Haleon
Haleon will be a new world-leader in consumer health with an exceptional portfolio of category-leading brands.
-
GSK provides update on phase III RSV maternal vaccine candidate programme
GSK gives update on RSV maternal vaccine candidate
-
China’s National Medical Products Administration approves Benlysta (belimumab) for adult patients with active lupus nephritis
First and only biologic approved in China for both systemic lupus erythematosus and lupus nephritis
-
GSK delivers FY 2021 reported sales of £34 billion, stable at AER, +5% CER; Total EPS 87.6p -24% AER, -13% CER and Adjusted EPS of 113.2p -2% AER, +9% CER
GSK delivers FY 2021 reported sales of £34 billion, stable at AER, +5% CER.
-
ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022
ViiV Healthcare to present new long-term findings at CROI 2022
-
GSK announces settlement between ViiV Healthcare and Gilead Sciences, Inc. resolving litigation relating to Biktarvy and ViiV’s dolutegravir patents and entry into a patent licence agreement
Gilead will make an upfront payment of $1.25 billion to ViiV Healthcare in the first quarter of 2022
-
ViiV Healthcare announces US FDA approval of Cabenuva (cabotegravir, rilpivirine) for use every two months, expanding the label of the first and only complete long-acting HIV treatment
Cabenuva is now approved for administration as few as six times a year for virologically suppressed adults living with HIV.
-
Tony Wood appointed Chief Scientific Officer designate, GSK
Tony Wood appointed Chief Scientific Officer designate, GSK
-
Update - GSK Consumer Healthcare
GlaxoSmithKline (GSK) plc today confirms it has received three unsolicited, conditional and non-binding proposals from Unilever plc
-
GSK and Vir Biotechnology announce United States government agreement to purchase additional supply of sotrovimab, authorised for the early treatment of COVID-19
600,000 additional doses to be supplied to the US Government for distribution in Q1 2022
-
ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV prevention
ViiV Healthcare announces US FDA approval of Apretude
-
GSK announces Sir Dave Lewis appointed Non-Executive Chair Designate of independent Consumer Healthcare company
GSK announces Sir Dave Lewis appointed Non-Executive Chair Designate of independent Consumer Healthcare company
-
Xevudy (sotrovimab) granted marketing authorisation by the European Commission for the early treatment of COVID-19
GSK and Vir are committed to the ongoing evaluation of sotrovimab as the COVID-19 landscape continues to evolve
-
GSK and Sanofi announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of phase III trial per independent Monitoring Board recommendation
Companies intend to file booster data with regulatory authorities following the phase III results
-
New data presented at ASH 2021 highlight potential of Blenrep (belantamab mafodotin-blmf) in combination with standard of care therapies in earlier lines of multiple myeloma treatment
GSK announced new data from the DREAMM-9 phase I trial and two GSK collaborative studies investigating the potential use of Blenrep.
